N/A N=15 Hidradenitis Suppurativa (HS) Tunneling Wounds
Hidradenitis Suppurativa
Primary: Change in Microbiome — 5.46; 3.88 colony forming units per ml (CFU/ml)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=161 Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Skin Diseases, Infectious
Primary: Skin Abscess Resolution — 4; 3 participants
Phase 3 N=30 Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
Refractory Bone or Joint Infections
Primary: Clinical Success at 6 Months — 18; 9; 3 Participants
Phase 3 N=23 Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Abscess
Primary: Number of Participants With Abscess Resolution — 11; 9 Participants
N/A N=300 Single Dose Monurol for Treatment of Acute Cystitis
Urinary Tract Infection
Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
Phase 2 N=6 Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess
Furunculosis
Primary: Number of Side-effects — 4; 2 Participants
Phase 4 N=50 Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
Phase 2 N=200 A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Major Cutaneous Abscess · Cellulitis · Erysipelas
Primary: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 91 participants
Phase 3 N=761 Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
Complicated Skin and Soft Tissue Infection
Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
N/A N=216 Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
Nasal Carriers of Staphylococcus Aureus
Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects
N/A N=265 Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
Skin Disease, Bacterial · Abscess
Primary: Treatment Failures — 9; 4 participants — p=0.25
Phase 2 N=150 Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
Skin Structure Infections · Bacterial Skin Diseases · Staphylococcal Skin Infections
Primary: Clinical Response at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 33; 37; 31 Participants
N/A N=36 Hydrogen Peroxide to the Wound Following Surgical Incision Affecting Cultures in Primary Shoulder Arthroplast
Primary Anatomic or Reverse Total Shoulder Arthroplasty
Primary: Number of Positive vs Negative Culture's Based on Skin Prep Method — 6; 6; 12; 11 Participants
Phase 4 N=146 Preventing Staphylococcal (Staph) Infection
Staphylococcal Infections
Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Phase 3 N=680 Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
Bacterial Infections
Primary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 291; 289; 25; 28 participants
Phase 3 N=698 Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
Bacterial Infections
Primary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 304; 297; 29; 21 participants
N/A N=80 Skin Prep to Reduce Postoperative Shoulder Infection
Shoulder Infection
Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68
Phase 2 N=225 Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
Urinary Tract Infections · Acute Pyelonephritis
Primary: Number of Participants With Clinical and Microbiological Response — 45; 46; 35 Participants
Phase 3 N=850 Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…